Actively Recruiting
Biomarkers in Different Types of Amyotrophic Lateral Sclerosis (ALS) Patients Being Treated With Edaravone
Led by Loma Linda University · Updated on 2025-05-21
160
Participants Needed
1
Research Sites
338 weeks
Total Duration
On this page
Sponsors
L
Loma Linda University
Lead Sponsor
T
Temple University
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is being conducted to help the investigators better understand how the new FDA approved medication Edaravone (also known as Radicava) works in subsets of patients with ALS. The investigators are also trying to understand if there are specific ALS patients, with different presentations of ALS, who might benefit most from this medication. Also, the investigators are following specific biomarkers to determine the optimal treatment duration in patients with different forms of ALS There is no study medication being offered in this trial. Edaravone is prescribed as part of regular care. In this trial we are collecting blood, urine, and spinal fluid samples in ALS patients who are taking Edaravone and ALS patients who are not taking Edaravone to measure certain markers that could indicate why the drug may be working in a specific type of ALS.
CONDITIONS
Official Title
Biomarkers in Different Types of Amyotrophic Lateral Sclerosis (ALS) Patients Being Treated With Edaravone
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of possible, probable, or definite ALS, or predominantly lower motor neuron disease, predominantly upper motor neuron disease, or bulbar ALS
- With or without cognitive involvement
- Willing to participate in the study
- Not receiving any experimental treatments
- Age between 18 and 85 years
- No prior use of Edaravone (Radicava)
- On a stable dose of Riluzole for at least 30 days or not taking Riluzole
- Male or female
- Females of childbearing age must use contraception
You will not qualify if you...
- Having an unstable medical illness
- Abnormal liver function greater than twice the upper limit of normal
- Unlikely to survive for 26 weeks
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Loma Linda University
Loma Linda, California, United States, 92354
Actively Recruiting
Research Team
I
Imran Qasim
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here